Skip to main content
close menu
close menu

Search UK HealthCare

Jill Kolesar, PharmD

Director, Early Phase Clinical Trials Center
Co-Director, Molecular Tumor Board
jill kolesar
  • About

    Faculty Rank

  • Publications


    1. Phenome-Wide Association Studies (PheWASs) Offer New Opportunities for Drug Repositioning. Rastegar-Mojarad M, Ye J, Kolesar JM, Lin SM and Hebbring SJ. Nat Biotechnol. Apr 7;33:342-5, 2015.
    2. Detection of a point mutation in NQO1 (DT diaphorase) in a patient with colon cancer. Kolesar JM, Burris H, Kuhn JG. J Natl Cancer Inst 87:1022 24, 1995.
    3. Implementation and clinical utility of an integrated academic-community regional molecular tumor board. Burkard ME, Deming D, Parsons K, Schuh M, Leal T, Uboha N, Lang J. Thompson M, Warren R, Bauman J, Mably M, Laffin J, Paschal C, Lager A, Lee K, Matkowskyj K, Buehler D, Rehrauer W, Kolesar J. JCO Precision Oncology, in press.
    4. A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers. Kolesar JM, Hoel R, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Krontiras H, Brouillette W, Muccio D, Kim K, Grubbs CJ, Bailey HE. Cancer Prev Res 3:1565-1570, 2010. PMCID: PMC3204611
    5. Prioritization of family member sequencing for the detection of rare variants. Sippy R, Kolesar JM, Darst BF, Engelman CD. BMC Proceedings 2016; 10 (S7):11.
  • Research

    Cancer Center Member

    Research Focus

    Clinical pharmacology and drug development of anticancer agents.


    • Drug Discovery, Delivery and Translational Therapeutics

    College & Department

    • College of Pharmacy
    • Department of Pharmacy Practice and Science

    For Referring Physicians

    567 Todd Building - BioPharm Complex
    789 South Limestone
    Lexington, KY 40536
    United States